Clinical trials: Ophthalmic Solutions
Dry Eye
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
The RENEW Trial is a Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in…
- Trial name
- NCT03879863
- Testing
- Reproxalap Ophthalmic Solution (0.25%) QID, Vehicle Ophthalmic Solution QID, Reproxalap Ophthalmic Solution (0.25%) QID to BID
- Where
- United States
- Volunteers
- 422 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting
To evaluate the IOP lowering efficacy of netarsudil ophthalmic solution 0.02% when used as monotherapy or when used concomitantly with other IOP-lowering agents in subjects with elevated IOP due to open angle glaucoma or ocular…
- Trial name
- NCT03808688
- Testing
- Netarsudil Ophthalmic Solution 0.02%
- Where
- 22 sites in United States
- Volunteers
- 261 people
- Sponsor
- Aerie Pharmaceuticals
Anesthesia, Local
A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population
A Phase 3, randomized, active-controlled, study in pediatric subjects. It is designed to evaluate the safety and anesthetic efficacy of one dose of AG-920 ophthalmic solution compared to Proparacaine Hydrochloride Ophthalmic…
- Trial name
- NCT05325853
- Testing
- AG-920, Proparacaine Ophthalmic
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- American Genomics, LLC
Dry Eye, Dry Eye Syndromes
Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye
Tangible Hydra-PEG is a novel coating technology designed to improve lens wettability, deposit resistance, and tear film breakup time.
- Trial name
- NCT03417505
- Testing
- Scleral lenses treated with Tangible Hydra-PEG, Untreated scleral lenses
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tangible Science
Allergic Conjunctivitis
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- NCT01881113
- Testing
- AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aciex Therapeutics, Inc.
Keratitis
Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis
The proposed 3-month study is a prospective, open-label, multicentre, phase IV, proof of concept study. The study is designed to assess the effect on the quality of vision of IKERVIS® (1mg/mL ciclosporin) eye drops administered…
- Trial name
- FAST (NCT03237936)
- Testing
- 1mg/mL ciclosporin
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Santen SAS
Dry Eye Disease
A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye
The purpose of this study is to evaluate the efficacy and safety of SI-614 ophthalmic solution compared with placebo in patients with dry eye
- Trial name
- SIDE (NCT05411367)
- Testing
- SI-614
- Where
- 6 sites in United States
- Volunteers
- 232 people
- Sponsor
- Seikagaku Corporation
Presbyopia
Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Safety and Efficacy Study of BRIMOCHOL™ vs. BRIMOCHOL™ F vs. Carbachol Monotherapy Topical Ophthalmic Solutions in Subjects with Emmetropic Phakic and Pseudophakic Presbyopia
- Trial name
- NCT04774237
- Testing
- BRIMOCHOL™, BRIMOCHOL™ F, Carbachol
- Where
- 3 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Visus Therapeutics
Dry Eye
Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease
Evaluate the tolerability, efficacy and safety of VOS versus Restasis® in subjects with mild to moderate Dry Eye Disease (DED).
- Trial name
- NCT03597139
- Testing
- Voclosporin Ophthalmic Solution, Restasis®
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Glaucoma
Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops
This study examines patient perceptions regarding the tolerability of two classes of glaucoma medication: bimatoprost and latanoprost.
- Trial name
- NCT02138461
- Where
- United States
- Volunteers
- 211 people
- Sponsor
- MDbackline, LLC
Dry Eye
Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)
SDP-4-CS201, is a Phase 2, multi-center, double-masked, randomized, vehicle-controlled, dose-response, parallel-group study designed to evaluate the ocular and systemic safety and efficacy of SDP-4 ophthalmic solution in subjects…
- Trial name
- SDP-4-CS201 (NCT03889886)
- Testing
- SDP-4 Ophthalmic Solution (0.1%), SDP-4 Ophthalmic Solution (1.0%), SDP-4 Ophthalmic Solution (3.0%)
- Where
- 26 sites in United States
- Volunteers
- 305 people
- Sponsor
- Silk Technologies, Ltd.
Dry Eye Disease
A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease
The purpose of this study is to assess the efficacy and safety of K-161 ophthalmic solution for the treatment of moderate to severe dry eye disease.
- Trial name
- NCT05403827
- Testing
- K-161
- Where
- 51 sites in United States
- Volunteers
- 644 people
- Sponsor
- Kowa Research Institute, Inc.
Ocular Hypertension, Glaucoma
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate the ocular and systemic safety of Netarsudil (AR-13324) Ophthalmic Solution, 0.02% q.d. and b.i.d. for 12 months compared to the active comparator Timolol Maleate Ophthalmic Solution, 0.5%.
- Trial name
- NCT02246764
- Testing
- AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Aerie Pharmaceuticals
Dry Eye Syndromes
Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease
This study will investigate the safety, efficacy and acceptability of two new eye drop formulations compared with Refresh Tears® in patients with dry eye disease.
- Trial name
- NCT01294384
- Testing
- carboxymethylcellulose sodium based New Eye Drop Formulation 1, carboxymethylcellulose sodium based New Eye Drop Formulation 2, carboxymethylcellulose sodium based Eye Drops
- Where
- 2 sites in Australia, Canada
- Volunteers
- 305 people
- Sponsor
- Allergan
Geographic Atrophy, Age-Related Macular Degeneration
Geographic Atrophy Treatment Evaluation
The purpose of this study was to evaluate the safety and efficacy of AL-8309B Ophthalmic Solution versus Vehicle administered as a topical ocular drop for the treatment for geographic atrophy (GA) secondary to age-related macular…
- Trial name
- GATE (NCT00890097)
- Testing
- AL-8309B Ophthalmic Solution, AL-8309B Vehicle
- Volunteers
- 772 people
- Sponsor
- Alcon Research
Dry Eye Syndromes
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
This study will evaluate the safety and efficacy of a new eye drop formulation in patients with dry eye disease.
- Trial name
- NCT02553772
- Testing
- Carboxymethylcellulose Based Eye Drop, Carboxymethylcellulose Sodium 0.5%
- Where
- 13 sites in United States, Australia
- Volunteers
- 242 people
- Sponsor
- Allergan
Dry Eye
A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease
A Multi-Center, Phase 2, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% Novel Formulation) Compared to Vehicle in Subjects…
- Trial name
- NCT03916042
- Testing
- Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Dry Eye
Tobramycin Tear Concentrations
To evaluate the Tobramycin tear concentration values of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension versus TOBREX® Ophthalmic Solution in normal volunteers.
- Trial name
- NCT00695435
- Testing
- TOBRADEX Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension, TOBREX Ophthalmic Solution
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Dry Eye Disease
Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease
SURF-200 is being studied in people experiencing an episodic flare-up of their dry eye disease. SURF-200 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.
- Trial name
- NCT04734210
- Testing
- 0.02% Betamethasone Sodium Phosphate, 0.04% Betamethasone Sodium Phosphate
- Where
- 28 sites in United States
- Volunteers
- 139 people
- Sponsor
- Surface Ophthalmics, Inc.
Pseudophakia, Inflammation
Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery
Investigate the intraocular pressure(pressure inside the eye) of patients who are treated with Lotemax after undergoing cataract surgery.
- Trial name
- NCT01344226
- Testing
- loteprednol 0.5% ophthalmic solution
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Toyos Clinic